Recent Advances in Theranostic Radiopharmaceuticals

Recent Advances in Theranostic Radiopharmaceuticals in Prostate Cancer: PSMA and Beyond
September 18, 2023 | 12:00 PM ET
Category: Radiopharmaceutical Sciences Council

Robert Flavell, MD, PhD


Joseph R. Osborne, MD, PhD, FACNM, Weill Cornell Medical College
Sarah M. Cheal, PhD, Weill Cornell Medical College 
Sangeeta Ray Banerjee, PhD, MS, Johns Hopkins School of Medicine
Francois Benard, MD, BC Cancer Agency Research Centre
Robert Flavell, MD, PhD

Course Summary
The purpose of this webinar to provide an update on new theranostic radiopharmaceuticals at the preclinical or early translational stage of development for imaging and treatment of prostate cancer. This will take the form of three moderated lectures followed by a panel discussion. The specific areas of discussion will include 1) the use of 225Ac-labeled antibodies for prostate cancer treatment, 2) the use of heterobivalent PSMA and FAPI targeting ligands for imaging and treatment and 3) strategies to reduce salivary gland toxicity in PSMA radioligand therapy through changes in radiopharmaceutical design. The emphasis is on cutting edge basic science and early translational advances that have a potential to make an impact on the clinic in the months and years to come. The target audience is scientists, physicians, pharmacists, technologists, and other professionals with an interest in the development of new theranostic agents for imaging and treatment of prostate cancer. This course will provide these professionals with an update on important new areas of radiopharmaceutical development, and the expected outcome is an improved understanding of the strengths and limitations of current technologies for prostate cancer theranostics, and cutting edge methodologies that may overcome them.

Course Objectives
Explain how 225Ac-labeled antibodies have the potential to treat prostate cancer.
Discuss strategies to overcome loss of PSMA resistance in prostate cancer theranostic design, including the use of heterobivalent targeting ligands.
Describe strategies to minimize salivary gland toxicity in PSMA therapy using new radiopharmaceutical designs.
CE Information
CE Credit applications for physicians, pharmacists, physicists and technologists are pending. Check back for updates regarding CE Credit status. 

9/18/2023 12:00 PM - 1:00 PM

Register for Another Webinar

Sign In to Register